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ABSTRACT
Background: An anti-programmed cell death protein 1 monoclonal antibody, 
nivolumab, is one of the most effective drugs for advanced melanoma. Tumor cell-
derived or immune cell-derived markers and clinical predictors such as serum lactate 
dehydrogenase (LDH) and cutaneous adverse events, have already been described 
as prognostic factors for advanced melanoma treated with nivolumab. We sought to 
identify further clinical predictors that can be determined in routine clinical practice.
Methods: We retrospectively analyzed clinical findings of 98 consecutive patients 
with unresectable stage III or IV melanoma treated with nivolumab, at the National 
Cancer Center Hospital or at Keio University Hospital, in Tokyo, Japan, between July 
2014 and July 2016. These patients had been administered nivolumab at a dose of 
2mg/kg every 3 weeks.
Results: As for pretreatment prognostic factors, ECOG performance status (PS) 
≥1, maximum tumor diameters of ≥30mm, elevated LDH and elevated C-reactive 
protein were significantly associated with poor overall survival (OS) (hazard ratio 
[HR] 0.29 [P<0.001], HR 0.40 [p=0.003], HR 0.29 [P<0.001], HR 0.42 [P=0.004], 
respectively) on univariate analysis. Among these factors, PS and LDH were identified 
as independent variables by multivariate analysis. As for early markers examined 
during therapy, patients with absolute lymphocyte count (ALC) ≥ 1000/μl (Week3: 
HR 0.40 [P=0.004], Week6: HR 0.33 [P=0.001]) and absolute neutrophil count (ANC) 
<4000/μl (Week3: HR 0.46 [P=0.014], Week6: HR 0.51 [P=0.046]) had significantly 
better OS.
Conclusion: ALC≥1000/μl and ANC<4000/μl during treatment appear to be early 
markers associated with OS. Nivolumab might have minimal efficacy in patients with 
a massive tumor burden.
INTRODUCTION
Advanced melanoma has historically been regarded 
as a disease with a poor prognosis, with a median overall 
survival (OS) of 8-10 months and a 5-year survival rate 
of 10% [1]. In recent years, the emergence of new drugs, 
BRAF inhibitors and immune-checkpoint blockades, 
have resulted in remarkable advances in the treatment 
of advanced melanoma and have improved patient 
outcomes. According to the NCCN guidelines version 
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2.2016, anti-programmed cell death protein 1 (PD-
1) antibodies (nivolumab and pembrolizumab) or the 
nivolumab/ipilimumab combination can serve as first-line 
immunotherapy for metastatic/unresectable melanoma, 
with single use of ipilimumab being recommended 
as second-line therapy. In Japan, nivolumab is the 
first immune-checkpoint inhibitor to be approved and 
has played the leading role in treatment of advanced 
melanoma since 2014. Recently, nivolumab was also 
approved for use in non-small-cell lung cancer [2, 3] and 
renal cell carcinoma [4].
Although immune-checkpoint inhibitors are used for 
all metastatic and unresectable melanomas, these agents 
are only effective for a portion of these malignancies and, 
above all, they are very expensive. Identifying biomarkers 
predicting efficacy and thereby allowing appropriate 
patients to be selected for these treatments is a crucial topic 
of ongoing research. Over the past several years, some 
biomarkers and clinical predictors of nivolumab efficacy 
in melanoma patients have been reported. The previously 
reported biomarkers were classified into two groups: 
tumor-derived immune biomarkers and immune cell-
derived biomarkers. The former include tumor cell PD-
L1 expression [5–7], tumor cell MHC-II expression [8], 
high tumor mutational load [9,10], and neoantigen [11]. 
The latter include the presence of CD8+ tumor-infiltrating 
lymphocytes (TILs) in tumor microenvironments [6, 12–
14], increased PD-L1 expression on immune cells [15], no 
increase in peripheral-blood regulatory T cells, no decrease 
in antigen (NY-ESO-1, MART-1 and gp100) specific T 
cells [6], specific inflammation and IFN-γ-related mRNA-
based signatures [16]. However, these biomarkers are not 
entirely reliable and their investigation is labor-intensive 
and thus impractical in daily clinical practice. On the other 
hand, predictors which are also routinely obtained clinical 
findings, such as serum lactate dehydrogenase (LDH) and 
cutaneous adverse events (AEs), have only been assessed 
by a small number of investigators [17, 18].
To enhance the efficacy of nivolumab, we analyzed 
simple predictors, focusing particularly on those easily 
obtained by routine laboratory testing.
RESULTS
Patient demographics
From July 2014 through July 2016, 98 patients were 
treated. Patient characteristics are summarized in Table 1.
The median patient age was 66.5 years (range, 17-
93) and 52 (53.1%) patients were men. PS was 0 to 1 in 
93.9% (N=92) of patients, and 87.7% (N=86) of patients 
had stage IV disease. While acral type is relatively 
common in Asia, more patients with mucosal melanoma 
participated in this study (Acral: 17.3%, CSD (chronically 
sun-damaged): 7.1%, Non-CSD: 20.4%, Mucosal: 36.7%, 
Others: 11.2% [10 patients had a choroidal origin, and 1 
patient had a lung origin], unknown: 7.1%). Overall, 49% 
(N=48) of patients had elevated LDH at baseline.
Prior treatments had been administered to 
71.4% patients (N=70). Among them, 24.5% (N=24) 
had received prior cytotoxic systemic chemotherapy 
(mainly Dacarbazine alone and combinations containing 
Dacarbazine), and 7.1% (N=7) had undergone 
transcatheter arterial chemoembolization. Radiotherapy 
had been administered to 18.4% (N=18) and some patients 
had also received immunotherapy (adjuvant IFN-β local 
injection: 12.2%, dendritic cell therapy 4.1%, Ipilimumab: 
3.1%, PEG IFN-α 2b:1%). Numbers of prior systemic 
therapies ranged one to four (Median: 1). Numbers of 
organs with metastatic disease ranged from zero to seven 
(Median: 2). Maximum diameters of tumors (MDT) 
ranged from 6 to 130 mm (Median: 30.3mm). The MDT 
sites varied (27 liver, 24 lymph node, 16 lung, 8 bone, 4 
subcutaneous, 4 gastrointestinal tract, 2 adrenal grand, 2 
pleura, 2 nasal cavity, 1 brain, 1 spleen, 1 gallbladder, 1 
pancreas, 1 intestinal membrane and 1 muscle. 3 patients 
had unmeasurable tumors.)
Baseline serum LDH values ranged from 137-2266 
(/μl) and the median was 231.5. LDH was elevated (upper 
limit of normal [ULN]: 229) in 51% (N=50) of patients. 
Baseline CRP ranged from 0.01-12.7 (mg/dl) and the 
median was 0.31. CRP (ULN: 0.29) was elevated in 51.6% 
(N=49, 3/98 patients were not tested) of patients.
Immune-related adverse events
In total, 52% (N=51) of patients experienced 
immune-related adverse events (irAEs). Most had grade 
(G) 1 AE (N=31). Major AEs included vitiligo (N=13), 
hypothyroidism (N=11), pruritis (N=10), rash (N=7) and 
malaise (N=5). Most of the AEs were mild (G1). In total, 
20 patients had AEs of G2 or greater severity (G2: 10, G3: 
6, G4: 4). G3 AEs included 2 Stevens Johnson Syndromes, 
1 adrenal insufficiency, 1 diarrhea, 1 uveitis and 1 
decreased platelet count. G4 AEs included 2 elevated CKs 
and 2 hyperglycemias.
Clinical responses and survival
The best response rate was 22.4% (2 CRs and 
20 PRs) and the overall response was 19.3% (2 CRs 
and 17 PRs). Two patients experienced PD before PR. 
Three patients experienced SD prior to PR. Two patients 
progressed to PD after having once been evaluated as 
showing PR. Five patients also showed PD after having 
once been given an evaluation of SD. Most remaining 
patients showed no change in response after the first 
evaluation or died after the confirmation of PD.
Median OS was 13.0 months (95%CI 5.7 to 20.3). 
Outcomes are summarized in Table 2.
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Table 1: Demographic factors and baseline patient characteristics (n=54)
Factor Category N (%)
Age <65 46(46.9)
≥65 52(53.1)
Median age (range) 66.5 (17-93)
Gender Male 52(53.1)
Female 46(46.9)
Stage III 12 (12.2)
IV 86 (87.7)
ECOG performance status 0 54 (55.1)
1 38(38.8)
2 5 (5.1)
3 1 (1.0)
Primary site Acral 17 (17.3)
CSD 7 (7.1)
Non-CSD 20 (20.4)
Mucosal 36 (36.7)
Others (Choroid) 11 (11.2)
Unknown 7 (7.1)
Prior therapy Chemotherapy Systemic chemotherapy 24 (24.5)
Transcatheter arterial 
chemoembolization 7 (7.1)
Radiotherapy 18 (18.3)
Immunotherapy Adjuvant IFN-β (local injection) 12 (12.2)
Dendritic cell therapy 4 (4.1)
Ipilimumab 3 (3.1)
PEG IFN-α 2b 1 (1.0)
Others (Molecular therapy) 8 (8.2)
None 28 (28.6)
Number of prior systemic 
therapies 0 28 (28.6)
1 49 (50.0)
2 13 (13.3)
3 6 (6.1)
4 2 (2.0)
Median 1
(Continued )
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Factor Category N (%)
Adverse events (Grade) 0 47(48.0)
1 31(30.6)
2 10(10.2)
3 6 (6.1)
4 4 (4.1)
Median 1
Baseline MDT (mm) <30 47 (49.5)
≥30 48 (50.5)
NA 3
Median (Range) 30.3 (5-130)
Baseline LDH (IU/L)
ULN=229 <230 48 (49.0)
≥230 50 (51.0)
Median (Range) 231.5 (137−2266)
Baseline CRP (mg/dl)
ULN=0.29 <0.30 46 (48.4)
≥0.30 49 (51.6)
NA 3
Median (Range) 0.31(0.01-12.7)
Baseline WBC count (x103/µl)
ULN=8.59 <8.60 90 (87.8)
≥8.60 8 (12.2)
Median (Range) 5.58 (2.4-15.9)
Baseline ANC (x103/µl) <4.0 53 (52)
≥4.0 45 (48)
Median (Range) 3.88(1.44-13.52)
Baseline ALC (x103/µl) <1.0 33 (33.7)
≥1.0 65 (66.3)
Median (Range) 1.17 (0.23-2.95)
Baseline AMC (x103/µl) <0.3 32 (32.7)
≥0.3 66 (67.3)
Median (Range) 0.35 (0.14-0.98)
Baseline AEC (x103/µl) <0.2 62 (74)
≥0.2 36 (26)
Median (Range) 0.12 (0.00-0.75)
ECOG, Eastern Cooperative Oncology Group; CSD, chronically sun-damaged (skin); LDH, lactate dehydrogenase; ULN, 
upper limit of normal; IFN, interferon; CRP, C-reactive protein; WBC, white blood cell; ANC, absolute neutrophil count; 
ALC, absolute lymphocyte count; AMC, absolute monocyte count; AEC, absolute eosinophil count; MDT, maximum 
diameter of tumors; NA, not available.
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Table 2: Clinical Responses and Survival
Best response CR 2/98 2.0% (95% CI: 0.3-7.2%)
PR 20/98 20.4% (95% CI: 12.9-29.7%)
SD 24/98 24.5% (95% CI: 16.4-34.2%)
PD 52/98 53.1% (95% CI: 42.7-63.2%)
Overall response CR 2/98 2.0% (95% CI: 0.3-7.2%)
PR 17/98 17.3% (95% CI: 10.4-26.3%)
SD 16/98 16.3% (95% CI: 9.6-25.2%)
PD 63/98 64.3% (95% CI: 54.0-73.7%)
OS (Months) Median 13.0 (95% CI: 5.7-20.3)
Baseline biomarker evaluation
Examination of the baseline findings revealed that 
patients with PS=0 had a significantly longer OS than 
those with PS≥1 (54 patients vs 44; HR 0.29, 95% CI 
0.16-0.53, P<0.001) (Figure 1A). Since there were only 
6 patients with PS≥2, the difference between PS≤1 and 
PS≥2 was not significant (P=0.190). Tumor size was also 
significantly associated with OS (MDT<30mm [N=47] 
vs ≥30mm [N=48]; HR 0.40, 95%CI 0.21-0.75, P=0.03) 
(Figure 1B). Sex, age, stage III or IV, primary site, prior 
therapy, and number of prior systemic therapies, likewise, 
showed no significant differences. Normal, versus 
elevated, baseline serum LDH and CRP also correlated 
significantly with longer OS (LDH: 48 patients vs 45; HR 
0.29, 95%CI 0.15−0.55, P<0.001, CRP: 46 vs 49; HR 
0.42, 95%CI 0.23-0.77, P=0.004) (Figure 1C, 1D).
Finally, we investigated whether baseline peripheral 
blood test values might be related to outcomes. We 
analyzed whether the white blood cell count, as well as 
ALC, ANC, AMC or AEC, showed any correlation with 
OS. Only non-significant trends suggesting relationships 
between baseline values and outcome were detected 
(Figure 2A, 2D and Supplementary Figure A, B).
Early markers of outcomes during therapy
We explored clinical data to identify early predictors 
of outcome during treatment.
ALC and ANC changes in responsive (CR+PR; 
best response) and non-responsive (PD; best response) 
patient subgroups during nivolumab therapy are shown in 
Figure 3. Median ALC increased slightly during the course 
of therapy in both groups. ALC values were clearly higher 
in responsive than in non-responsive patients. The median 
ANC of the responsive subgroup was decreased during 
the course of therapy. On the other hand, the ANC of the 
non-responsive patients was essentially unchanged. We 
stratified patients into two ALC groups based on a cut-off 
value of ≥1000/μL (high ALC) vs <1000/μL (low ALC). 
We also stratified Kaplan-Meier survival curves based on 
the ALCs at baseline and after the 1st and 2nd nivolumab 
doses (Week 3 and Week 6 after treatment initiation), 
as shown in Figure 2A-C. While baseline ALC was not 
significantly associated with OS (HR 0.63, 95%CI 0.35-
1.14 P=0.124), ALC during nivolumab therapy showed 
a clear and significant association with OS (Week3: HR 
0.40, 95%CI 0.21-0.77, P=0.004; Week6: HR 0.33, 95%CI 
0.17-0.65, P=0.001).
We also stratified patients into high and low ANC, 
AMC and AEC groups during treatment. While there was 
no significant difference between high ANC (≥4000μL) 
and low ANC (<4000/μL) cases at baseline (HR 0.88, 
95%CI 0.49-1.58, P=0.665), ANC during nivolumab 
therapy showed a significant association with OS (Week3: 
HR 0.46, 95%CI 0.24-0.87, P=0.014, Week6: HR 0.51, 
95%CI 0.26-1.00, P=0.046). Kaplan-Meier survival 
curves based on ANCs are presented in Figure 2D-F.
Similarly, high AEC at Week 3 was significantly 
associated with better OS while there was no significant 
difference at Baseline or at Week 6 (≥100μL vs <100μL, 
Baseline; HR 0.77, 95%CI 0.41-1.45, p=0.418, 
Week3; HR 0.49, 95%CI 0.27-0.91, p=0.024, Week6; 
HR 0.55, 95%CI 0.28-1.05, p=0.068). (Supplementary 
Figure E-G)
According to these findings, high ALC and low 
ANC during treatment appear to be associated with 
a good prognosis. High AEC during treatment also 
suggestedbetter OS. Associations of WBC counts and 
AMC during treatment with outcome showed only non-
significant trends. Univariate conditional survival analysis 
evaluating relationships between OS and laboratory data 
at each time point (baseline [Week 0], week 3, and week 
6 after initial nivolumab dose) is summarized in Table 3.
In addition, patients with AEs (of all grades) had 
significantly better OS (HR 0.54, 95%CI 0.30-0.99, 
P=0.043). Notably, the 13 patients experiencing only 
vitiligo had good outcomes (HR 0.15, 95%CI 0.04-0.63, 
P=0.003). (Supplementary Figure C, D)
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DISCUSSION
Comparison with ipilimumab
To date, a number of potential markers for 
ipilimumab efficacy have been described. As for baseline 
peripheral blood test values, low LDH, CRP, AMC, and 
myeloid-derived suppressor cells (MDSC), as well as high 
AEC, CD4+CD25+FOXP3+-regulatory T cells frequencies, 
and relative lymphocyte counts are reportedly associated 
with a good prognosis [19–22]. As to early blood-based 
markers predicting responses to therapy, increased ALC 
[19, 23, 24], increased rate ALC to WBC [25], low 
neutrophil to lymphocyte ratio (NLR) [26], increased 
AEC [26], increased inducible co-stimulator [26, 27] 
on circulating CD4+ T cells, decreased MDSC [28, 29], 
increased Th12 cell inducibility [30], and melanoma 
markers on circulating cells (Melan-A, gp100, MAGE-3 
and MIA) [31] have been reported.
As previously described, several potential 
biomarkers for nivolumab have been suggested in recent 
years [5–18]. As to routinely-obtained clinical findings, 
only cutaneous AEs and LDH have been reported [17, 18].
In this study, as in prior investigations of 
ipilimumab, LDH and CRP were shown to be baseline 
prognostic factors. Multivariate analysis of relationships 
between pretreatment levels of PS, MDT, CRP and LDH 
with OS are shown in Table 4A. PS and LDH were 
identified as independent variables, while MDT and CRP 
were not. MDT and CRP might simply reflect tumor 
burden or disease progression, in parallel with rising LDH. 
In addition, these pretreatment factors could simply reflect 
Figure 1: Kaplan-Meier curves in terms of OS by each prognostic factor. PS≧1 A., MDT B., elevated LDH C. and elevated 
CRP D. were associated with significantly poorer outcomes.
Oncotarget77410www.impactjournals.com/oncotarget
patients’ conditions, rather than nivolumab efficacy itself. 
If true, these results raise the possibility that nivolumab 
may not have sufficient efficacy in patients with a massive 
tumor burden.
As to early markers for outcome, patients with high 
ALC and low ANC at week 3 and week 6 had significantly 
longer OS. Multivariate analysis of relationships between 
ALC and ANC at 3 and 6 weeks are shown in Table 4B. 
Figure 2: Kaplan-Meier curves in terms of OS by ALC and ANC. ALC and ANC after the 1st nivolumab dose correlated with 
survival.
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ALC and ANC were found to be independent variables. 
Good outcomes of patients with ALC≥1000 during 
treatment were likewise obtained in an ipilimumab study 
[19, 23, 24]. Though median ALC was also elevated in PD 
patients (ALC was increased as compared with baseline; 
CR+PR: 3W 13/22, 6W 15/22, PD: 3W 21/52, 6W 22/52), 
ALCs of non-responsive patients tended to be lower than 
those of the responsive subgroup (Figure 3).
As for NLR, while baseline NLR was not 
significantly associated with OS, the patients with NLR≥4 
at Week 3 tended to have poorer OS than those with lower 
NLR (comparison between NLR<4 and NLR≥4, Baseline: 
Figure 3: Changes in the ALC and the ANC of responsive (CR+PR) and non-responsive (PD) patients receiving 
nivolumab are shown. Median ALC increased slightly as the therapy proceeded. The median ALC of responsive patients was higher 
than that of non-responsive patients. The median ANC of the responsive subgroup decreased during the course of therapy. The ANC of 
non-responsive patients was essentially unchanged.
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HR 0.65, 95%CI 0.36-1.17, P=0.147, Week3: HR 0.36, 
95%CI 0.19-0.67, P= 0.001, Week6: HR 0.28, 95%CI 
0.28-1.08, P=0.056) (Supplementary Figure H-J).
Our results appear to be consistent with those of 
studies examining early markers in patients receiving 
ipilimumab treatment.
AEs and prognosis
AEs including vitiligo and rash were reported to 
be good prognostic factors for melanoma patients treated 
with nivolumab [17]. Similar results were obtained in this 
study.
Delayed response
According to previous reports, some melanoma 
patients treated with ipilimumab experienced initial 
enlargement of tumor lesions, confirmed by biopsy to be 
attributable to inflammatory cell infiltrates or necrosis, 
followed by a subsequent decrease in tumor burden [32]. 
Such immune-related delayed clinical responses have 
also been observed in studies of nivolumab. One study 
of metastatic melanoma patients treated with nivolumab 
found that 10% (11 of 107 patients) experienced delayed 
responses [33]. However, in this study, only 2% (2 of 
98 patients) experienced PD prior to PR, raising the 
possibility that the delayed response might be very limited 
in previously treated patients or limited to tumors arising 
from acral and mucosal sites, except in cases with CSD 
skin.
In addition, second or later evaluations yielded 
results not differing from those of the first, in most cases. 
Given these results and the major financial burden, we 
should be wary of continuing this treatment in patients 
initially evaluated as showing PD.
Table 3: Univariate conditional survival analysis evaluating relationships between OS and laboratory data at each 
time point (baseline [Week 0], week 3, and week 6 after initial nivolumab dose)
Baseline (N=98) Week 3 (N=93) Week 6 (N=87)
Factor HR (95%CI), P HR (95%CI), P HR (95%CI), P
LDH<230 0.29 (0.15-0.55), <0.001 0.28(0.15-0.53), <0.001 0.27(0.14-0.53), <0.001
CRP<0.30 0.42 (0.23-0.77), 0.004 0.24(0.12-0.48), <0.001 0.26(0.13-0.54), <0.001
WBC<8600 1.06 (0.42-2.69), 0.907 0.60(0.29-1.23), 0.156 1.02(0.40-2.64), 0.963
ALC≥1000 0.63 (0.88-2.86), 0.124 0.40(0.21-0.77), 0.004 0.33(0.17-0.65), 0.001
ANC<4000 0.88(0.49-1.58), 0.665 0.46(0.24-0.87), 0.014 0.51(0.26-1.00), 0.046
AMC<300 0.72(0.38-1.37), 0.307 0.83(0.38-1.79), 0.631 1.57(0.78-3.15), 0.200
AEC≥100 0.77(0.41-1.45), 0.418 0.49(0.27-0.91), 0.024 0.55(0.28-1.05), 0.068
Table 4A: Multivariate analysis of relationships of pretreatment baseline PS, MDT, CRP and LDH with OS (N=93)
Factor HR (95%CI) P
PS=0 (PS<1) 0.41(0.21-0.77), 0.006
MDT<30 0.59(0.31-1.15), 0.120
LDH<230 0.39(0.19-0.82), 0.012
CRP<0.30 0.90(0.45-1.99), 0.904
Table 4B: Multivariate analysis of relationships of Week 3 (N=93) and Week 6 (N=88)
ALC and ANC with OS
Factor HR (95%CI) P
Week 3 ALC≥1000 0.43(0.24-0.77), 0.002
Week 3 ANC<4000 0.65(0.39-1.08), 0.007
Week 6 ALC≥1000 0.33(0.19-0.58), 0.001
Week6 ANC<4000 0.82(0.48-1.38), 0.042
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Though external validation is essential before 
hypothetical models can be applied in clinical practice, our 
preliminary results merit a large cohort analysis evaluating 
these factors in greater detail.
In conclusion, high ALC and low ANC after the 1st 
nivolumab dose may serve as early markers associated 
with better OS in patients with advanced melanoma, based 
on our retrospective observations. Furthermore, PS, MDT, 
and CRP at baseline, along with the already established 
LDH, are potential prognostic markers for advanced 
melanoma cases. In addition, nivolumab appears to have 
an insufficient effect in patients with massive tumor 
burdens and, on rare occasion, a delayed response may 
occur in previously treated patients. Therefore, it might 
be worth considering the discontinuation of nivolumab 
administration in patients initially evaluated as showing 
PD, especially when such patients still have other 
treatment options. Further prospective study is warranted 
to assess these possibilities.
MATERIALS AND METHODS
Patients
We retrospectively analyzed all patients at the 
National Cancer Center Hospital (NCCH), Tokyo, 
Japan and Keio University Hospital, Tokyo, Japan, with 
advanced melanoma, treated between 2014 and 2016 
using nivolumab, for whom outcomes could be evaluated. 
Eligibility criteria included unresectable stage III and IV 
melanoma, all of which had been histologically confirmed 
at the NCCH or Keio University. The patients who had 
been administered oral steroids were excluded considering 
the influences of these drugs on laboratory findings.
The items determined prior to treatment included 
age, sex, ECOG performance status (PS), stage, primary 
site, prior therapy, number of prior systemic therapies, 
number of organs with metastasis, maximum tumor 
diameters (in the event of lymph nodes harboring the 
largest tumors, the minor axis was measured) and 
peripheral blood tests (including serum LDH, C-reactive 
protein [CRP], absolute lymphocyte count [ALC], absolute 
neutrophil count [ANC], absolute monocyte count 
[AMC], absolute eosinophil count [AEC] and the ratios 
of the parameters to each other). Prior to each nivolumab 
administration, patients underwent repeat peripheral blood 
testing and AEs were evaluated. We continued to measure 
these parameters, during the treatment period, to determine 
whether they predicted outcomes.
Treatment and response
Nivolumab was administered at 2mg/kg 
intravenously over 60 minutes every 3 weeks. This is 
the established dosing method for nivolumab covered by 
the national health insurance system of Japan. Patients 
continued this therapy until they were evaluated as 
showing progressive disease (PD) twice in succession, 
died or experienced unacceptable AEs. Patients who 
stopped nivolumab administration continued to be 
observed until death or until they were lost to follow-up.
Patients usually underwent radiographic imaging 
every 12 weeks and were evaluated for response by 
computed tomography (CT) according to the immune-
related response evaluation criteria in solid tumors 
(irRESIST) criteria (version 1.1) [34, 35]. The response 
categories were complete response (CR), partial response 
(PR), stable disease (SD) and PD.
Endpoint
The efficacy evaluation was based on survival rather 
than on progression free survival or best objective tumor 
response. The latter parameters were not considered to be 
appropriate for evaluating the actual benefits of nivolumab 
treatment. When baseline parameters were evaluated as 
prognostic factors, survival time was calculated as the 
period from the first dose of nivolumab to the date of death 
or the last documented follow-up.
When laboratory findings during treatment were 
evaluated as early markers, OS was defined based on 
the period from the date on which the patient underwent 
testing (3 and 6 weeks after starting treatment) until the 
date of death or last follow-up.
Statistical analysis
Demographic factors and baseline patient 
characteristics of the study participants were 
summarized. The OS rate was estimated for each group 
with the Kaplan-Meier method. The log-rank test was 
used to compare survival between groups, and the hazard 
ratio (HR) and its 95% confidence interval (95% CI) 
were estimated employing Cox’s proportional hazards 
model in the univariate analysis. Cox’s proportional 
hazards models were also used for multivariate analyses. 
The conditional Cox regression model was used to 
evaluate the associations between early laboratory 
biomarkers after an initial dose of nivolumab and OS. 
For example, when evaluating the effect of a biomarker 
at Week 3, i.e. with the log conditional hazard function 
for given a survival time being greater than that at Week 
3, the conditional Cox regression model was used. The 
95% CI for proportions were estimated with the Clopper 
Pearson method.
The significance level for all tests was two-sided α 
= 0.05. All analyses were performed using the Statistical 
Package for Social Science (SPSS, Chicago, Ill) vesion23 
for MAC.
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Supplementary Figure S1: Kaplan-Meier curves in terms of OS by each prognostic factor. Baseline WBC A., AMC B., 
AEC E., and NLR H. were not associated with OS, significantly. Occurrence of AE C. especially vitiligo D. was significantly associated 
with better OS. AEC ≥100/μl F. and NLR <4 I. at Week 3 were associated with better OS significantly, while there was no significant 
difference at Week 6 G, J.
